The 10 Biden officials to watch on the Covid-19 response – STAT
Biden has already named dozens of scientists, administrators, and policymakers to his Covid-19 team. Can they coalesce?
Related Articles
Listen: A new obesity startup, an acquisition gone wrong, & the future of Teledoc
This week on “The Readout LOUD” podcast: How does a startup compete in the rapidly evolving field of weight loss drugs? And how did a…
Covid ignited a global controversy over what is an airborne disease. The WHO just expanded its definition
A WHO advisory committee outlined a new set of definitions that more accurately reflect the science of airborne disease transmission.
Microsoft is selling AI in health care, and helping to set its standards. Is that a problem?
For some, Microsoft’s deep involvement in setting standards for the use of AI in health care raises questions about “regulatory capture.”
Elevance’s private equity deal will form $4 billion primary care company
Health insurer Elevance’s private equity deal will form a $4 billion primary care company.
Health disparities and premature deaths run deep, even in best-performing states
A new analysis of health inequities shows that every state has deep racial and ethnic disparities in the performance of their health care systems.
Chuck Schumer’s broken promise on affordable insulin
For more than two years, Sen. Chuck Schumer has been promising to hold a vote to make insulin affordable for people with all types of…
Dana-Farber retracts string of studies in systematic review of data integrity
“It is good to see this institution taking a harder stance against sloppy science and intentional data falsification that many institutes have done in the…
USDA faulted for disclosing scant information about outbreaks of H5N1 avian flu in cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess…
How BIO CEO’s cozy relationship with WuXi soured
As lawmakers take aim at WuXi Apptec, the issue is testing the ability of BIO’s CEO to navigate a domestic policy issue that is tangled…
WuXi and BIO’s grip-and-grin
Our latest edition of D.C. Diagnosis includes the backstory of BIO’s relationship with WuXi, a major endorsement of site-neutral payments, and the financial fallout of…